Incyclix Shares INX-315 Phase 1/2 Data For Resistant Cancers
13 Dec 2024 //
GLOBENEWSWIRE
Incyclix Bio Announces Trial Collaboration with Lilly for INX-315
18 Nov 2024 //
GLOBENEWSWIRE
Incyclix Bio Expands Board of Directors with Appointment of Norman
12 Nov 2024 //
GLOBENEWSWIRE
Incyclix Bio Names Dr. Andrew Beelen As VP Of Clinical Development
20 Aug 2024 //
GLOBENEWSWIRE
Incyclix Bio Announces FDA Clearance of Investigational NDA for INX-315
28 Feb 2023 //
GLOBENEWSWIRE